184 related articles for article (PubMed ID: 23795874)
21. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial.
Liebschutz JM; Crooks D; Herman D; Anderson B; Tsui J; Meshesha LZ; Dossabhoy S; Stein M
JAMA Intern Med; 2014 Aug; 174(8):1369-76. PubMed ID: 25090173
[TBL] [Abstract][Full Text] [Related]
22. Utilization of buprenorphine and methadone among opioid users who inject drugs.
Tsui JI; Burt R; Thiede H; Glick SN
Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
[TBL] [Abstract][Full Text] [Related]
23. Recent incarceration and buprenorphine maintenance treatment outcomes among human immunodeficiency virus-positive patients.
Riggins DP; Cunningham CO; Ning Y; Fox AD
Subst Abus; 2017; 38(3):297-302. PubMed ID: 27715904
[TBL] [Abstract][Full Text] [Related]
24. A latent class analysis of self-reported clinical indicators of psychosocial stability and adherence among opioid substitution therapy patients: do stable patients receive more unsupervised doses?
Larance B; Carragher N; Mattick RP; Lintzeris N; Ali R; Degenhardt L
Drug Alcohol Depend; 2014 Sep; 142():46-55. PubMed ID: 25015687
[TBL] [Abstract][Full Text] [Related]
25. Concomitant Heroin and Cocaine Use among Opioid-Dependent Patients during Methadone, Buprenorphine or Morphine Opioid Agonist Therapy.
Gastberger S; Baumgartner MR; Soyka M; Quednow BB; Hulka LM; Herdener M; Seifritz E; Mutschler J
Eur Addict Res; 2019; 25(4):207-212. PubMed ID: 31067528
[TBL] [Abstract][Full Text] [Related]
26. Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine.
Jordan CJ; Cao J; Newman AH; Xi ZX
Neuropharmacology; 2019 Nov; 158():107609. PubMed ID: 31009632
[TBL] [Abstract][Full Text] [Related]
27. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees.
Samples H; Williams AR; Olfson M; Crystal S
J Subst Abuse Treat; 2018 Dec; 95():9-17. PubMed ID: 30352671
[TBL] [Abstract][Full Text] [Related]
28. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community.
Biondi BE; Vander Wyk B; Schlossberg EF; Shaw A; Springer SA
Addict Sci Clin Pract; 2022 Mar; 17(1):15. PubMed ID: 35255967
[TBL] [Abstract][Full Text] [Related]
29. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence.
Fiellin DA; Pantalon MV; Chawarski MC; Moore BA; Sullivan LE; O'Connor PG; Schottenfeld RS
N Engl J Med; 2006 Jul; 355(4):365-74. PubMed ID: 16870915
[TBL] [Abstract][Full Text] [Related]
30. Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration.
Manhapra A; Petrakis I; Rosenheck R
Am J Addict; 2017 Sep; 26(6):572-580. PubMed ID: 28472543
[TBL] [Abstract][Full Text] [Related]
31. Buprenorphine Treatment for Probationers and Parolees.
Gordon MS; Kinlock TW; Schwartz RP; Couvillion KA; Sudec LJ; O'Grady KE; Vocci FJ; Shabazz H
Subst Abus; 2015; 36(2):217-25. PubMed ID: 24701967
[TBL] [Abstract][Full Text] [Related]
32. Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia.
Larance B; Degenhardt L; Grebely J; Nielsen S; Bruno R; Dietze P; Lancaster K; Larney S; Santo T; Shanahan M; Memedovic S; Ali R; Farrell M
Addiction; 2020 Jul; 115(7):1295-1305. PubMed ID: 31860767
[TBL] [Abstract][Full Text] [Related]
33. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
[TBL] [Abstract][Full Text] [Related]
34. Development of an integrated digital health intervention to promote engagement in and adherence to medication for opioid use disorder.
Langdon KJ; Ramsey S; Scherzer C; Carey K; Ranney ML; Rich J
Addict Sci Clin Pract; 2020 Apr; 15(1):16. PubMed ID: 32349790
[TBL] [Abstract][Full Text] [Related]
35. Three-Year Retention in Buprenorphine Treatment for Opioid Use Disorder Among Privately Insured Adults.
Manhapra A; Agbese E; Leslie DL; Rosenheck RA
Psychiatr Serv; 2018 Jul; 69(7):768-776. PubMed ID: 29656707
[TBL] [Abstract][Full Text] [Related]
36. The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine/naloxone for the treatment of opioid dependence.
Sullivan LE; Moore BA; O'Connor PG; Barry DT; Chawarski MC; Schottenfeld RS; Fiellin DA
Am J Addict; 2010; 19(1):53-8. PubMed ID: 20132122
[TBL] [Abstract][Full Text] [Related]
37. Association between methamphetamine use and retention among patients with opioid use disorders treated with buprenorphine.
Tsui JI; Mayfield J; Speaker EC; Yakup S; Ries R; Funai H; Leroux BG; Merrill JO
J Subst Abuse Treat; 2020 Feb; 109():80-85. PubMed ID: 31810594
[TBL] [Abstract][Full Text] [Related]
38. Retention of Patients With Multiple Vulnerabilities in a Federally Qualified Health Center Buprenorphine Program: Pennsylvania, 2017-2018.
Weinstein LC; Iqbal Q; Cunningham A; Debates R; Landistratis G; Doggett P; Silverio A
Am J Public Health; 2020 Apr; 110(4):580-586. PubMed ID: 32078355
[No Abstract] [Full Text] [Related]
39. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
Rhee TG; Rosenheck RA
Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
[TBL] [Abstract][Full Text] [Related]
40. Impact of early childhood trauma on retention and phase advancement in an outpatient buprenorphine treatment program.
Kumar N; Stowe ZN; Han X; Mancino MJ
Am J Addict; 2016 Oct; 25(7):542-8. PubMed ID: 27629823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
